278 related articles for article (PubMed ID: 11032968)
1. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
Fischer PM; Lane DP
Curr Med Chem; 2000 Dec; 7(12):1213-45. PubMed ID: 11032968
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
3. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
7. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells.
Coats S; Whyte P; Fero ML; Lacy S; Chung G; Randel E; Firpo E; Roberts JM
Curr Biol; 1999 Feb; 9(4):163-73. PubMed ID: 10074425
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
9. Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells.
Schmidt M; Fan Z
Oncogene; 2001 Sep; 20(43):6164-71. PubMed ID: 11593424
[TBL] [Abstract][Full Text] [Related]
10. The cyclin-dependent kinase inhibitor p27(Kip1) induces N-terminal proteolytic cleavage of cyclin A.
Bastians H; Townsley FM; Ruderman JV
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15374-81. PubMed ID: 9860976
[TBL] [Abstract][Full Text] [Related]
11. ATP-site directed inhibitors of cyclin-dependent kinases.
Gray N; Détivaud L; Doerig C; Meijer L
Curr Med Chem; 1999 Sep; 6(9):859-75. PubMed ID: 10495356
[TBL] [Abstract][Full Text] [Related]
12. [Cyclin-dependent kinase inhibitors in mammal cells].
Jiang H; Wang YC
Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):107-12. PubMed ID: 9592231
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27.
Vlach J; Hennecke S; Amati B
EMBO J; 1997 Sep; 16(17):5334-44. PubMed ID: 9311993
[TBL] [Abstract][Full Text] [Related]
14. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
15. A novel cyclinE/cyclinA-CDK inhibitor targets p27(Kip1) degradation, cell cycle progression and cell survival: implications in cancer therapy.
Dai L; Liu Y; Liu J; Wen X; Xu Z; Wang Z; Sun H; Tang S; Maguire AR; Quan J; Zhang H; Ye T
Cancer Lett; 2013 Jun; 333(1):103-12. PubMed ID: 23354589
[TBL] [Abstract][Full Text] [Related]
16. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.
Lee MH; Reynisdóttir I; Massagué J
Genes Dev; 1995 Mar; 9(6):639-49. PubMed ID: 7729683
[TBL] [Abstract][Full Text] [Related]
17. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation.
Tanner FC; Boehm M; Akyürek LM; San H; Yang ZY; Tashiro J; Nabel GJ; Nabel EG
Circulation; 2000 May; 101(17):2022-5. PubMed ID: 10790340
[TBL] [Abstract][Full Text] [Related]
19. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.
McInnes C; Andrews MJ; Zheleva DI; Lane DP; Fischer PM
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):57-69. PubMed ID: 12678915
[TBL] [Abstract][Full Text] [Related]
20. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.
Rossi KA; Markwalder JA; Seitz SP; Chang CH; Cox S; Boisclair MD; Brizuela L; Brenner SL; Stouten PF
J Comput Aided Mol Des; 2005 Feb; 19(2):111-22. PubMed ID: 16075305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]